Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-γ agonist, after a single oral administration in healthy female subjects.

@article{Park2014TolerabilityAP,
  title={Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-γ agonist, after a single oral administration in healthy female subjects.},
  author={Min Kyu Park and Tae-Eun Kim and Jaewoo Kim and Chin Suk Kim and Seo Hyun Yoon and Joo Youn Cho and I. C. Jang and Kyung-Sang Yu and Kyoung Soo Lim},
  journal={Clinical drug investigation},
  year={2014},
  volume={34 7},
  pages={467-74}
}
BACKGROUND AND OBJECTIVES Lobeglitazone is a recently approved peroxisome proliferator-activated receptor-γ agonist for the treatment of type 2 diabetes mellitus in Korea. The purpose of this study was to investigate the pharmaco kinetic properties of lobeglitazone in healthy females and to compare these with historical data in healthy males. METHODS This study was designed as a block-randomized, double-blind, placebo-controlled, parallel-group study. A single 2 or 4 mg oral dose of… CONTINUE READING